MeiraGTx Holdings plc Operating Lease Cost
MeiraGTx Holdings plc (MGTX) reported Operating Lease Cost of $1.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- MeiraGTx Holdings plc operating lease, cost for the quarter ending 2026-06-30 was $1.02M, a 8.63% decline year-over-year.
- MeiraGTx Holdings plc operating lease, cost for the quarter ending 2026-03-31 was $1.17M, a 8.96% decline year-over-year.
- MeiraGTx Holdings plc operating lease, cost for the quarter ending 2025-12-31 was $1.09M, a 17.97% decline year-over-year.
- MeiraGTx Holdings plc operating lease, cost for the quarter ending 2025-09-30 was $1.28M, a 10.64% decline year-over-year.
- MeiraGTx Holdings plc operating lease, cost for fiscal 2025 was $4.76M, a 15.38% decline from fiscal 2024.
- MeiraGTx Holdings plc operating lease, cost for fiscal 2024 was $5.63M, a 2.87% increase from fiscal 2023.
- MeiraGTx Holdings plc operating lease, cost for fiscal 2023 was $5.47M, a 3.13% increase from fiscal 2022.
- MeiraGTx Holdings plc operating lease, cost for fiscal 2022 was $5.31M, a 6.10% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.02M 10-Q · filed 2026-08-13 | $2.19M 10-Q · filed 2026-08-13 | $3.28M derived: sum of 3 quarters · filed 2026-08-13 | $4.55M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.17M 10-Q · filed 2026-05-14 | $2.26M derived: sum of 2 quarters · filed 2026-05-14 | $3.54M derived: sum of 3 quarters · filed 2026-05-14 | $4.65M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.37M derived: sum of 2 quarters · filed 2026-03-30 | $3.48M derived: sum of 3 quarters · filed 2026-08-13 | $4.76M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.28M 10-Q · filed 2025-11-13 | $2.39M derived: sum of 2 quarters · filed 2026-08-13 | $3.67M 10-Q · filed 2025-11-13 | $5.00M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.11M 10-Q · filed 2026-08-13 | $2.40M 10-Q · filed 2026-08-13 | $3.73M derived: sum of 3 quarters · filed 2026-08-13 | $5.16M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.28M 10-Q · filed 2026-05-14 | $2.61M derived: sum of 2 quarters · filed 2026-05-14 | $4.04M derived: sum of 3 quarters · filed 2026-05-14 | $5.48M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.76M derived: sum of 2 quarters · filed 2026-03-30 | $4.20M derived: sum of 3 quarters · filed 2026-03-30 | $5.63M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.43M 10-Q · filed 2025-11-13 | $2.87M derived: sum of 2 quarters · filed 2025-11-13 | $4.30M 10-Q · filed 2025-11-13 | $5.67M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-14 | $2.87M 10-Q · filed 2025-08-14 | $4.24M derived: sum of 3 quarters · filed 2025-08-14 | $5.62M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-13 | $2.81M derived: sum of 2 quarters · filed 2025-05-13 | $4.18M derived: sum of 3 quarters · filed 2025-05-13 | $5.55M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.74M derived: sum of 2 quarters · filed 2025-03-13 | $4.11M derived: sum of 3 quarters · filed 2025-03-13 | $5.47M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $1.37M 10-Q · filed 2024-11-13 | $2.74M derived: sum of 2 quarters · filed 2024-11-13 | $4.10M 10-Q · filed 2024-11-13 | $5.42M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.37M 10-Q · filed 2024-08-12 | $2.73M 10-Q · filed 2024-08-12 | $4.05M derived: sum of 3 quarters · filed 2024-08-12 | $5.36M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $1.36M 10-Q · filed 2024-05-09 | $2.68M derived: sum of 2 quarters · filed 2024-05-09 | $3.99M derived: sum of 3 quarters · filed 2024-05-09 | $5.33M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $2.63M derived: sum of 2 quarters · filed 2024-03-15 | $3.97M derived: sum of 3 quarters · filed 2024-03-15 | $5.31M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $1.31M 10-Q · filed 2023-11-14 | $2.65M derived: sum of 2 quarters · filed 2023-11-14 | $3.99M 10-Q · filed 2023-11-14 | $5.25M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-10 | $2.67M 10-Q · filed 2023-08-10 | $3.94M derived: sum of 3 quarters · filed 2023-08-10 | $5.24M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.31M 10-Q · filed 2023-05-11 | $2.60M derived: sum of 2 quarters · filed 2023-05-11 | $3.90M derived: sum of 3 quarters · filed 2023-05-11 | $5.18M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.58M derived: sum of 2 quarters · filed 2023-03-14 | $3.87M derived: sum of 3 quarters · filed 2023-03-14 | $5.00M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.29M 10-Q · filed 2022-11-10 | $2.58M derived: sum of 2 quarters · filed 2022-11-10 | $3.71M 10-Q · filed 2022-11-10 | $4.57M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.28M 10-Q · filed 2022-08-11 | $2.42M 10-Q · filed 2022-08-11 | $3.27M derived: sum of 3 quarters · filed 2022-08-11 | $4.10M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.14M 10-Q · filed 2022-05-12 | $1.99M derived: sum of 2 quarters · filed 2022-05-12 | $2.82M derived: sum of 3 quarters · filed 2022-05-12 | $3.72M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $852.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.68M derived: sum of 2 quarters · filed 2022-03-10 | $2.58M derived: sum of 3 quarters · filed 2022-03-10 | $3.42M 10-K · filed 2022-03-10 | $3.42M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $830.00K 10-Q · filed 2021-11-10 | $829.81K 10-Q · filed 2020-11-05 | $1.73M derived: sum of 2 quarters · filed 2021-11-10 | $2.57M 10-Q · filed 2021-11-10 | $2.57M 10-Q · filed 2020-11-05 | $3.82M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $901.00K 10-Q · filed 2021-08-11 | $901.04K 10-Q · filed 2020-08-06 | $1.74M 10-Q · filed 2021-08-11 | $1.74M 10-Q · filed 2020-08-06 | $2.99M derived: sum of 3 quarters · filed 2021-08-11 | $3.88M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $1.03M 10-Q · filed 2021-05-11 | $1.03M 10-Q · filed 2020-05-07 | $2.09M derived: sum of 2 quarters · filed 2021-05-11 | $2.98M derived: sum of 3 quarters · filed 2021-05-11 | $3.21M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.96M derived: sum of 2 quarters · filed 2021-03-11 | $2.18M derived: sum of 3 quarters · filed 2021-03-11 | $2.38M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $897.31K 10-Q · filed 2020-11-05 | $1.12M derived: sum of 2 quarters · filed 2020-11-05 | $1.32M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $224.04K 10-Q · filed 2020-08-06 | $6.74K 10-Q · filed 2019-08-07 | $433.19K 10-Q · filed 2020-08-06 | $13.37K 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $6.63K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |